抗凝血酶Ⅲ活性与慢加急性肝衰竭患者人工肝治疗结局的相关性

肝脏 ›› 2021, Vol. 26 ›› Issue (7): 770-775.

抗凝血酶Ⅲ活性与慢加急性肝衰竭患者人工肝治疗结局的相关性

毛燕群, 周学士, 王霞, 苏婷婷, 杜合娟, 过小叶, 周凌霄, 邱源旺

214000 无锡市第五人民医院肝病科

收稿日期:2020-08-27 出版日期:2021-07-31 发布日期:2021-09-02
通讯作者: 周学士,Email:moka861220@163.com
基金资助:
无锡市医学青年人才(QNRC051);无锡市卫生计生委科研项目(Q201831)

Study on the correlation between antithrombin III activity and short-term prognosis of acute-on-chronic liver failure patients treated with artificial liver support system

MAO Yan-qun, ZHOU Xue-shi, WANG Xia, SU Ting-ting, DU He-juan, GUO Xiao-ye, ZHOU Ling-xiao, QIU Yuan-wang

Department of Hepatology, Wuxi NO.5 People's Hospital, Jiangsu 214005, China

Received:2020-08-27 Online:2021-07-31 Published:2021-09-02
Contact: ZHOU Xue-shi,Email:moka861220@163.com

摘要/Abstract

摘要： 目的分析抗凝血酶Ⅲ活性与慢加急性肝衰竭(acute-on-chronic liver failure,ACLF)患者行人工肝治疗短期疗效及预后的相关性。方法回顾性分析2012年1月1日至2019年6月30日无锡市第五人民医院感染科ICU收治的236例行人工肝治疗的ACLF患者。记录患者入院时的血常规、肝功能、国际标准化比值(international normalized ratio,INR)、抗凝血酶Ⅲ活性等指标,计算入院时MELD评分,评价人工肝治疗后30 d疗效、90 d生存结局。计量资料采用t检验,计数资料采用卡方检验,不符合正态分布的计量资料采用秩和检验。Logistic回归分析人工肝疗效和患者结局的影响因素。结果人工肝治疗有效139例,90 d死亡63例。回归分析提示抗凝血酶Ⅲ活性(OR=1.118,95% CI 1.082~1.156,P<0.01)是影响人工肝疗效的独立影响因素;TBil(OR=1.008,95% CI 1.004~1.012,P<0.01)、INR(OR=1.109,95% CI 1.076~1.505,P=0.025)、AT-Ⅲ活性(OR=0.911,95% CI 0.881~0.943,P<0.01)、MELD评分(OR=1.090,95% CI 1.052~1.115,P=0.034)是影响患者90 d结局的独立影响因素。结论抗凝血酶Ⅲ活性与ACLF患者行人工肝治疗短期疗效及短期预后有相关性。

关键词: 抗凝血酶III, 肝衰竭, 人工肝, 疗效, 预后

Abstract: Objective To analyze the correlation of antithrombin III (AT-III) activity with short-term efficacy and prognosis of acute-on-chronic liver failure (ACLF) patients treated with artificial liver support system. Methods A retrospective analysis was performed in 236 ACLF patients treated with artificial liver support system in our hospital from January 1, 2012 to June 30, 2019. The blood routine, liver function, international normalized ratio (INR), and AT-Ⅲ activity were recorded, and the model for end-stage liver disease (MELD) score was calculated at the time of admission. The 30-day efficacy and 90-day survival rate of artificial liver support were evaluated. The t-test and rank sum test were used for measurement data, and the chi-square test was used for count data. The influential factors for the efficacy of artificial liver and patient outcome were analyzed by Logistic regression. Results Artificial liver support was effective in 139 patients, and 63 patients died during the 90-day follow-up. Regression analysis showed that AT-Ⅲ activity (OR=1.118, 95% CI 1.082-1.156, P=0.000) was an independent factor affecting the efficacy of artificial liver. Total bilirubin (OR=1.008, 95% CI 1.004-1.012, P=0.000), INR (OR=1.109, 95% CI 1.076-1.505, P=0.025), AT-Ⅲ activity (OR=0.911, 95% CI 0.881-0.943, P=0.000), and MELD score (OR=1.090, 95% CI 1.052-1.115, P=0.034) were independent factors affecting the 90-day survival of ACLF patients. Conclusion The short-term efficacy of artificial liver support system and short-term prognosis of ACLF was correlated with AT-Ⅲ activity.

Key words: Antithrombin Ⅲ, Liver failure, Artificial liver support system, Efficacy, Prognosis

毛燕群, 周学士, 王霞, 苏婷婷, 杜合娟, 过小叶, 周凌霄, 邱源旺. 抗凝血酶Ⅲ活性与慢加急性肝衰竭患者人工肝治疗结局的相关性[J]. 肝脏, 2021, 26(7): 770-775.

MAO Yan-qun, ZHOU Xue-shi, WANG Xia, SU Ting-ting, DU He-juan, GUO Xiao-ye, ZHOU Ling-xiao, QIU Yuan-wang. Study on the correlation between antithrombin III activity and short-term prognosis of acute-on-chronic liver failure patients treated with artificial liver support system[J]. Chinese Hepatolgy, 2021, 26(7): 770-775.

参考文献

[1] Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut, 2018, 67:2181-2191.
[2] Qin G, Shao JG, Wang B, et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore), 2014, 93:e338.
[3] Xiao LL, Xu XW, Huang KZ, et al. Artificial liver support system improves short-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a propensity score analysis. Biomed Res Int, 2019, 2019:3757149.
[4] 中华医学会感染病学分会肝衰竭与人工肝学组. 非生物型人工肝治疗肝衰竭指南(2016年版). 中华临床感染病杂志. 中华临床感染病杂志, 2016, 9:97-103.doi: 10.3760/cma.j.issn.1674-2397.2016.02.001.
[5] Hoefer J, Ulmer H, Kilo J, et al. Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support. J Thorac Cardiovasc Surg, 2017, 153:1374-1382.
[6] Pereyra D, Offensperger F, Klinglmueller F, et al. Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity. PLoS One, 2017, 12:e0175359.
[7] 周学士,叶阳群,毛燕群. 抗凝血酶III活性对慢加急性肝衰竭患者预后的预测价值. 中华传染病杂志, 2020, 38:105-110.
[8] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 中华肝脏病杂志,2019, 27:18-26.
[9] Li MR, Huang ZY, Cai CJ, et al. Effect of artificial liver support system on the survival rate of high risk patients after liver transplantation. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2010, 22:12-15.
[10] Montejo Gonzalez JC, Catalan Gonzalez M, Meneu Diaz JC, et al. Artificial liver support system in acute liver failure patients waiting liver transplantation. Hepatogastroenterology, 2009, 56:456-461.
[11] Fan Z, EnQiang C, Yao DL, et al. Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure treated with an artificial liver support system. PLoS One, 2017, 12:e0175332.
[12] Qin S, Tang SH, Wang XH, et al. Value of serum alpha-fetoprotein for the prognostic evaluation of hepatitis B virus-related acute-on-chronic liver failure treated with artificial liver. Zhonghua Gan Zang Bing Za Zhi, 2020, 28:69-72.
[13] Kim HY, Chang Y, Park JY, et al. Characterization of acute-on-chronic liver failure and prediction of mortality in Asian patients with active alcoholism. J Gastroenterol Hepatol, 2016, 31:427-433.
[14] Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia, 2008, 14:1229-1239.
[15] Croles FN, Lukens MV, Mulder R, et al. Monitoring of heparins in antithrombin-deficient patients. Thromb Res, 2019, 175:8-12.
[16] Perdigoto DN, Figueiredo P, Tome L. The role of the CLIF-C of and the 2016 MELD in prognosis of cirrhosis with and without acute-on-chronic liver failure. Ann Hepatol, 2019, 18:48-57.
[17] 王成成, 黄芬. 慢加急性(亚急性)肝衰竭及慢性肝衰竭预后危险因素分析. 临床内科杂志, Journal of Clinical Internal Medicine, 2015, 32:112-115.
[18] Yi ZQ, Lu MH, Xu XW, et al. A novel prognostic score for acute-on-chronic hepatitis B liver failure. J Huazhong Univ Sci Technolog Med Sci, 2015, 35:87-92.